Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Importance of Off-Label Options for Treating Serious Lung Diseases.

O'Sullivan BP.

Ann Am Thorac Soc. 2016 Nov;13(11):1879-1880. No abstract available.

PMID:
27831808
2.

Comparison of Nasal Potential Difference and Intestinal Current Measurements as Surrogate Markers for CFTR Function.

Wilschanski M, Yaakov Y, Omari I, Zaman M, Martin CR, Cohen-Cymberknoh M, Shoseyov D, Kerem E, Dasilva D, Sheth S, Uluer A, O╩╝Sullivan BP, Freedman S.

J Pediatr Gastroenterol Nutr. 2016 Nov;63(5):e92-e97.

PMID:
27496797
3.

Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices.

Orenstein DM, O'Sullivan BP, Quinton PM.

Glob Adv Health Med. 2015 Nov;4(6):8-57. doi: 10.7453/gahmj.2015.123. Epub 2015 Nov 1. No abstract available.

4.

Targeting nonsense-mediated cystic fibrosis: is it premature to stop now?

O'Sullivan BP.

Lancet Respir Med. 2014 Jul;2(7):509-11. doi: 10.1016/S2213-2600(14)70108-0. Epub 2014 May 15. No abstract available.

PMID:
24836206
5.

Pricing for orphan drugs: will the market bear what society cannot?

O'Sullivan BP, Orenstein DM, Milla CE.

JAMA. 2013 Oct 2;310(13):1343-4. doi: 10.1001/jama.2013.278129. No abstract available.

PMID:
24084916
6.

Infection control in cystic fibrosis: share and share alike.

O'Sullivan BP, Sassetti CM.

Lancet. 2013 May 4;381(9877):1517-9. doi: 10.1016/S0140-6736(13)60740-0. Epub 2013 Mar 29. No abstract available.

PMID:
23541536
7.

Empyema in a woman with cystic fibrosis: a cautionary tale.

Coates A, Schaefer O, Uy K, O'Sullivan BP.

Case Rep Pulmonol. 2013;2013:159508. doi: 10.1155/2013/159508. Epub 2013 Mar 5.

8.

Evolution of pancreatic function during the first year in infants with cystic fibrosis.

O'Sullivan BP, Baker D, Leung KG, Reed G, Baker SS, Borowitz D.

J Pediatr. 2013 Apr;162(4):808-812.e1. doi: 10.1016/j.jpeds.2012.10.008. Epub 2012 Dec 11.

PMID:
23245194
9.

A patient with asthma seeks medical advice.

O'Sullivan BP, Zwerdling RG, Kremer T.

N Engl J Med. 2012 May 3;366(18):1740-1; author reply 1742. doi: 10.1056/NEJMc1203718. No abstract available. Erratum in: N Engl J Med. 2012 Sep 13;367(11):1073.

PMID:
22551143
10.

Pulmonary complications of systemic vasculitides.

O'Sullivan BP.

Paediatr Respir Rev. 2012 Mar;13(1):37-43. doi: 10.1016/j.prrv.2011.04.002. Epub 2011 May 6. Review.

PMID:
22208792
11.

Using hyperpolarized 3He MRI to evaluate treatment efficacy in cystic fibrosis patients.

Sun Y, O'Sullivan BP, Roche JP, Walvick R, Reno A, Baker D, Mansour JK, Albert MS.

J Magn Reson Imaging. 2011 Nov;34(5):1206-11. doi: 10.1002/jmri.22724. Epub 2011 Sep 19.

PMID:
21932361
12.

Burkholderia pseudomallei infection in a child with cystic fibrosis: acquisition in the Western Hemisphere.

O'Sullivan BP, Torres B, Conidi G, Smole S, Gauthier C, Stauffer KE, Glass MB, Gee JE, Blaney D, Smith TL.

Chest. 2011 Jul;140(1):239-242. doi: 10.1378/chest.10-3336.

PMID:
21729895
13.

Cystic fibrosis newborn screening: using experience to optimize the screening algorithm.

Hale JE, Parad RB, Dorkin HL, Gerstle R, Lapey A, O'Sullivan BP, Spencer T, Yee W, Comeau AM.

J Inherit Metab Dis. 2010 Oct;33(Suppl 2):S255-61. doi: 10.1007/s10545-010-9117-3. Epub 2010 Jun 3.

PMID:
20521170
14.

Inhaled aztreonam.

O'Sullivan BP, Yasothan U, Kirkpatrick P.

Nat Rev Drug Discov. 2010 May;9(5):357-8. doi: 10.1038/nrd3170.

PMID:
20431562
15.

The clinical approach to lung disease in patients with cystic fibrosis.

O'Sullivan BP, Flume P.

Semin Respir Crit Care Med. 2009 Oct;30(5):505-13. doi: 10.1055/s-0029-1238909. Epub 2009 Sep 16. Review.

PMID:
19760538
16.

Cystic fibrosis.

O'Sullivan BP, Freedman SD.

Lancet. 2009 May 30;373(9678):1891-904. doi: 10.1016/S0140-6736(09)60327-5. Epub 2009 May 4. Review.

PMID:
19403164
17.

Oropharyngeal flora in healthy infants: observations and implications for cystic fibrosis care.

Carlson D, McKeen E, Mitchell M, Torres B, Parad R, Comeau AM, O'Sullivan BP.

Pediatr Pulmonol. 2009 May;44(5):497-502. doi: 10.1002/ppul.21029.

PMID:
19360845
18.

Cystic fibrosis pulmonary guidelines: airway clearance therapies.

Flume PA, Robinson KA, O'Sullivan BP, Finder JD, Vender RL, Willey-Courand DB, White TB, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee.

Respir Care. 2009 Apr;54(4):522-37.

19.

By the sweat of our brows: how salty should a person be?

O'Sullivan BP, Zwerdling RG.

J Pediatr. 2008 Dec;153(6):735-6. doi: 10.1016/j.jpeds.2008.09.010. No abstract available.

PMID:
19014812
20.

Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.

Flume PA, O'Sullivan BP, Robinson KA, Goss CH, Mogayzel PJ Jr, Willey-Courand DB, Bujan J, Finder J, Lester M, Quittell L, Rosenblatt R, Vender RL, Hazle L, Sabadosa K, Marshall B; Cystic Fibrosis Foundation, Pulmonary Therapies Committee.

Am J Respir Crit Care Med. 2007 Nov 15;176(10):957-69. Epub 2007 Aug 29.

PMID:
17761616
21.

Cystic fibrosis heterozygotes do not have increased platelet activation.

Tarnow I, Michelson AD, Frelinger AL 3rd, Linden MD, Li Y, Fox ML, Barnard MR, O'Sullivan BP.

Thromb Res. 2007;121(2):159-62. Epub 2007 May 29.

PMID:
17532368
22.

Guidelines for implementation of cystic fibrosis newborn screening programs: Cystic Fibrosis Foundation workshop report.

Comeau AM, Accurso FJ, White TB, Campbell PW 3rd, Hoffman G, Parad RB, Wilfond BS, Rosenfeld M, Sontag MK, Massie J, Farrell PM, O'Sullivan BP; Cystic Fibrosis Foundation.

Pediatrics. 2007 Feb;119(2):e495-518.

PMID:
17272609
23.

Potential utility of plasma fatty acid analysis in the diagnosis of cystic fibrosis.

Batal I, Ericsoussi MB, Cluette-Brown JE, O'Sullivan BP, Freedman SD, Savaille JE, Laposata M.

Clin Chem. 2007 Jan;53(1):78-84. Epub 2006 Nov 27.

24.

Early pulmonary manifestation of cystic fibrosis in children with the DeltaF508/R117H-7T genotype.

O'Sullivan BP, Zwerdling RG, Dorkin HL, Comeau AM, Parad R.

Pediatrics. 2006 Sep;118(3):1260-5.

PMID:
16951024
25.

The inflammatory role of platelets in cystic fibrosis.

O'Sullivan BP, Michelson AD.

Am J Respir Crit Care Med. 2006 Mar 1;173(5):483-90. Epub 2005 Dec 9. Review.

PMID:
16339920
26.

Communications systems and their models: Massachusetts parent compliance with recommended specialty care after positive cystic fibrosis newborn screening result.

Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB.

J Pediatr. 2005 Sep;147(3 Suppl):S98-100.

PMID:
16202793
27.

Challenges in implementing a successful newborn cystic fibrosis screening program.

Comeau AM, Parad R, Gerstle R, O'Sullivan BP, Dorkin HL, Dovey M, Haver K, Martin T, Eaton RB.

J Pediatr. 2005 Sep;147(3 Suppl):S89-93. Review.

PMID:
16202791
28.

Sweat testing infants detected by cystic fibrosis newborn screening.

Parad RB, Comeau AM, Dorkin HL, Dovey M, Gerstle R, Martin T, O'Sullivan BP.

J Pediatr. 2005 Sep;147(3 Suppl):S69-72.

PMID:
16202787
29.

Platelet activation in cystic fibrosis.

O'Sullivan BP, Linden MD, Frelinger AL 3rd, Barnard MR, Spencer-Manzon M, Morris JE, Salem RO, Laposata M, Michelson AD.

Blood. 2005 Jun 15;105(12):4635-41. Epub 2005 Feb 10.

30.

Interleukin 8 secretion from monocytes of subjects heterozygous for the deltaF508 cystic fibrosis transmembrane conductance regulator gene mutation is altered.

Zaman MM, Gelrud A, Junaidi O, Regan MM, Warny M, Shea JC, Kelly C, O'Sullivan BP, Freedman SD.

Clin Diagn Lab Immunol. 2004 Sep;11(5):819-24.

31.

Population-based newborn screening for genetic disorders when multiple mutation DNA testing is incorporated: a cystic fibrosis newborn screening model demonstrating increased sensitivity but more carrier detections.

Comeau AM, Parad RB, Dorkin HL, Dovey M, Gerstle R, Haver K, Lapey A, O'Sullivan BP, Waltz DA, Zwerdling RG, Eaton RB.

Pediatrics. 2004 Jun;113(6):1573-81.

PMID:
15173476
32.

Use of nasopharyngoscopy in the evaluation of children with noisy breathing.

O'Sullivan BP, Finger L, Zwerdling RG.

Chest. 2004 Apr;125(4):1265-9.

PMID:
15078733
33.

Survey of breast-feeding practices and outcomes in the cystic fibrosis population.

Parker EM, O'Sullivan BP, Shea JC, Regan MM, Freedman SD.

Pediatr Pulmonol. 2004 Apr;37(4):362-7.

PMID:
15022134
34.

Association of cystic fibrosis with abnormalities in fatty acid metabolism.

Freedman SD, Blanco PG, Zaman MM, Shea JC, Ollero M, Hopper IK, Weed DA, Gelrud A, Regan MM, Laposata M, Alvarez JG, O'Sullivan BP.

N Engl J Med. 2004 Feb 5;350(6):560-9.

35.

Treatment of bronchiolitis.

Zwerdling RG, O'Sullivan BP.

N Engl J Med. 2003 Oct 2;349(14):1384-5; author reply 1384-5. No abstract available.

PMID:
14523149
36.
37.

Risks and complications of nonbronchoscopic bronchoalveolar lavage in a pediatric intensive care unit.

O'Sullivan BP.

Pediatr Pulmonol. 2002 Jul;34(1):87-8; author reply 88. No abstract available.

PMID:
12112804
38.

Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium.

Perricone MA, Morris JE, Pavelka K, Plog MS, O'Sullivan BP, Joseph PM, Dorkin H, Lapey A, Balfour R, Meeker DP, Smith AE, Wadsworth SC, St George JA.

Hum Gene Ther. 2001 Jul 20;12(11):1383-94.

PMID:
11485630
39.

Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. I. Methods, safety, and clinical implications.

Joseph PM, O'Sullivan BP, Lapey A, Dorkin H, Oren J, Balfour R, Perricone MA, Rosenberg M, Wadsworth SC, Smith AE, St George JA, Meeker DP.

Hum Gene Ther. 2001 Jul 20;12(11):1369-82.

PMID:
11485629
40.

Tracheal bronchus: a cause of prolonged atelectasis in intubated children.

O'Sullivan BP, Frassica JJ, Rayder SM.

Chest. 1998 Feb;113(2):537-40.

PMID:
9498980
41.

Acute lung injury in endotoxemic pigs: role of leukotriene B4.

VanderMeer TJ, Menconi MJ, O'Sullivan BP, Larkin VA, Wang H, Sofia M, Fink MP.

J Appl Physiol (1985). 1995 Mar;78(3):1121-31.

PMID:
7775306
42.

Localized pneumothorax with lobar collapse and diffuse obstructive airway disease.

Nimkin K, Kleinman PK, Zwerdling RG, Spevak MR, O'Sullivan BP.

Pediatr Radiol. 1995;25(6):449-51.

PMID:
7491198
43.

Prior exposure to endotoxin exacerbates lipopolysaccharide-induced hypoxemia and alveolitis in anesthetized swine.

Wollert PS, Menconi MJ, Wang H, O'Sullivan BP, Larkin V, Allen RC, Fink MP.

Shock. 1994 Nov;2(5):362-9.

PMID:
7743363
44.
45.

Bactericidal/permeability-increasing protein ameliorates acute lung injury in porcine endotoxemia.

Vandermeer TJ, Menconi MJ, O'Sullivan BP, Larkin VA, Wang H, Kradin RL, Fink MP.

J Appl Physiol (1985). 1994 May;76(5):2006-14.

PMID:
8063663
46.

A novel leukotriene B4-receptor antagonist in endotoxin shock: a prospective, controlled trial in a porcine model.

Fink MP, O'Sullivan BP, Menconi MJ, Wollert PS, Wang H, Youssef ME, Fleisch JH.

Crit Care Med. 1993 Dec;21(12):1825-37.

PMID:
8252886
47.

A fifteen-year-old boy with eosinophilia and pulmonary infiltrates.

O'Sullivan BP, Nimkin K, Gang DL.

J Pediatr. 1993 Oct;123(4):660-6. No abstract available.

PMID:
8410525
48.

LY255283, a novel leukotriene B4 receptor antagonist, limits activation of neutrophils and prevents acute lung injury induced by endotoxin in pigs.

Wollert PS, Menconi MJ, O'Sullivan BP, Wang H, Larkin V, Fink MP.

Surgery. 1993 Aug;114(2):191-8.

PMID:
8393594
49.

Effect of granulocyte colony-stimulating factor on systemic and pulmonary responses to endotoxin in pigs.

Fink MP, O'Sullivan BP, Menconi MJ, Wollert SP, Wang H, Youssef ME, Bellelsle JM.

J Trauma. 1993 Apr;34(4):571-7; discussion 577-8.

PMID:
7683731
50.

Supplemental Content

Loading ...
Support Center